Crown Laboratories has finalized an agreement with Eclipse, a medical technology company, to acquire its global aesthetics-focused assets. Crown will integrate the Eclipse products into its Aesthetics business unit to complement its SkinPen Precision and other brands.
Jeff Bedard, president and CEO of Crown, said, “We pride ourselves on being at the forefront of today’s aesthetics market by developing and delivering best-in-class medical technologies and products that are exceptionally safe and effective. This strategic acquisition furthers Crown’s mission to drive innovation and provide superior products and customer service to aesthetic providers around the world. Eclipse’s excellent products will broaden our product line and customer base, domestically and internationally.”
Paul O’Brien, CEO of Eclipse, said, “We are thrilled to have completed this transaction with Crown. The combination of Eclipse’s innovative product offerings with Crown’s leadership position in the aesthetics market will undoubtedly expand the reach and optimize the range of services health care professionals can provide to their patients.”
